FDA Biologics (BLA & Biosimilars)Original article
OTP Town Hall: Cell Therapy CMC Readiness for Late-Stage INDs - 09/05/2024
Neutral
AI Analysis
Summary
FDA's Office of Therapeutic Products hosted a virtual town hall on September 5, 2024, to discuss CMC (chemistry, manufacturing, and controls) readiness requirements for late-stage INDs in cell therapy and tissue-engineered products.
Importance:2/10
Sentiment:
0.00
cell therapytissue engineeringCMCINDregulatory guidance
Read the original article
Published by FDA Biologics (BLA & Biosimilars) on September 15, 2026 7:59 PM